Treatment of hepatitis C before and after liver transplantation

Garcia-Retortillo, 2002, Hepatitis C virus kinetics during and immediately after liver transplantation, Hepatology, 35, 680, 10.1053/jhep.2002.31773 Berenguer, 2000, HCV-related fibrosis progression following liver transplantation: increase in recent years, J Hepatol, 32, 673, 10.1016/S0168-8278(00)80231-7 Berenguer, 2000, Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation, Hepatology, 32, 852, 10.1053/jhep.2000.17924 Crespo, 2012, Viral hepatitis in liver transplantation, Gastroenterology, 142, 1373, 10.1053/j.gastro.2012.02.011 Lange, 2013, Perspectives and challenges of interferon-free therapy for chronic hepatitis C, J Hepatol, 58, 583, 10.1016/j.jhep.2012.10.019 Lens, 2014, Interferon-free regimens in the liver-transplant setting, Semin Liver Dis, 34, 58, 10.1055/s-0034-1371011 Iacobellis, 2007, Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study, J Hepatol, 46, 206, 10.1016/j.jhep.2006.08.020 Curry, 2015, Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study, Gastroenterology, 148, 100, 10.1053/j.gastro.2014.09.023 Afdhal, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N Engl J Med, 370, 1889, 10.1056/NEJMoa1402454 Afdhal, 2014, Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection, N Engl J Med, 370, 1483, 10.1056/NEJMoa1316366 Poordad, 2014, ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis, N Engl J Med, 370, 1973, 10.1056/NEJMoa1402869 Zeuzem, 2014, Sofosbuvir and ribavirin in HCV genotypes 2 and 3, N Engl J Med, 370, 1993, 10.1056/NEJMoa1316145 Nelson, 2015, All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study, Hepatology, 61, 1127, 10.1002/hep.27726 Reddy, 2014, Ledipasvir/sofosbuvir with ribavirin for the treatment of HCD in patients with postpostransplant recurrence: preliminary results of a prospective multicenter study, Hepatology, 60, 200A Manns, 2015, Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post-liver transplantation patients with HCV infection: preliminary results of the SOLAR-2 trial, J Hepatol, 62, S187, 10.1016/S0168-8278(15)30003-9 Poordad, 2015, Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study, J Hepatol, 62, S261, 10.1016/S0168-8278(15)30154-9 Welzel, 2015, Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program, J Hepatol, 62, S619, 10.1016/S0168-8278(15)30975-2 Reddy, 2015, All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: report from HCV-target, J Hepatol, 62, S193, 10.1016/S0168-8278(15)30014-3 Curry, 2013, Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation, Hepatology, 58, 314 Afdhal, 2015, Effects of long term viral suppression with sobosbuvir+ribavirin on hepatic venous pressure gradient in HCV-infected patients and portal hypertension, Abstr J Hepatol, 62, S269, 10.1016/S0168-8278(15)30167-7 Olysio product information. [cited 01.06.15]; Available in: http://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Kathri, 2012, Pharmacokinetics and safety of co-administered ABT-450 plus ritonavir (ABT-450/r), ABT-267 and ABT-333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate and severe hepatic impairment, Hepatology, 56, 555A Gambato, 2014, Treatment options in patients with decompensated cirrhosis, pre- and postpostransplantation, J Hepatol, 61, S120, 10.1016/j.jhep.2014.07.020 Dvory-Sobol, 2015, Long-term persistance of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir, Abstr J Hepatol, 62, S221, 10.1016/S0168-8278(15)30073-8 Krishnan, 2015, Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir, ombitasvir and dasabuvir-based regimens, Abstr J Hepatol, 62, S220, 10.1016/S0168-8278(15)30071-4 Belli, 2007, Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study, Liver Transpl, 13, 733, 10.1002/lt.21093 Neumann, 2004, Fibrosis progression after liver transplantation in patients with recurrent hepatitis C, J Hepatol, 41, 830, 10.1016/j.jhep.2004.06.029 Forman, 2002, The association between hepatitis C infection and survival after orthotopic liver transplantation, Gastroenterology, 122, 889, 10.1053/gast.2002.32418 Charlton, 2002, Pre-emptive treatment of recurrent hepatitis C infection, Liver Transpl, 8, S50, 10.1053/jlts.2002.35859 Donato, 2014, Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?, Liver Int, 35, 1, 10.1111/liv.12646 Tavio, 2015, Prophylaxis of HCV reinfection in HIV-HCV recipients by starting direct-acting antiviral agents therapy during liver transplantation, Liver Transpl, 21, 1327, 10.1002/lt.24204 Coilly, 2013, Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience, J Hepatol, 60, 78, 10.1016/j.jhep.2013.08.018 Burton, 2014, A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy, J Hepatol, 61, 508, 10.1016/j.jhep.2014.04.037 Faisal, 2014, Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience, Ann Hepatol, 13, 525, 10.1016/S1665-2681(19)31252-9 Forns, 2014, Interim SVR12 results from the telaprevir phase 3B REPLACE study in treatment-naive stable liver transplant patients with genotype 1 HCV infection, J Hepatol, 60, S481 Charlton, 2014, Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation, Gastroenterology, 148, 108, 10.1053/j.gastro.2014.10.001 Forns, 2015, Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation, Hepatology, 61, 1485, 10.1002/hep.27681 Pungpapong, 2013, Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation, Liver Transpl, 19, 690, 10.1002/lt.23669 Kwo, 2014, An interferon-free antiviral regimen for HCV after liver transplantation, N Engl J Med, 371, 2375, 10.1056/NEJMoa1408921 Reddy, 2014, Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study, Hepatology, 60, 200A Leroy, 2014, High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV-recurrence after liver transplantation: The ANRS CO23 CUPILT study, Hepatology, 60, 207A Samuel, 2015, Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post-liver transplantation patients with HCV infection: an integrated safety analysis of the SOLAR-1 and SOLAR-2 trials, J Hepatol, S620, 10.1016/S0168-8278(15)30977-6 Coilly, 2015, The association of sofosbuvir and daclataavir for treating severe recurrence of HCV infection after liver transplantation: results from a large french prospective multicentric ANRS CO23 CULPIT cohort, J Hepatol, 62, S236, 10.1016/S0168-8278(15)30103-3 Forns, 2015, On-treatment virologic responde and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: interim data from the phase II SATURN study, J Hepatol, 62, S191, 10.1016/S0168-8278(15)30011-8 Jacobson, 2015, Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child-ough class B cirrhosis (C-SALT part A), J Hepatol, 62, S193, 10.1016/S0168-8278(15)30015-5